Abstract
The identification of specific genetic mutations that can be targeted is transforming the treatment of ovarian cancer. One of these mutations is in BRCA, a mutation that leads to homologous recombination deficiency. PARP inhibitors are now available which improve survival in those with BRCA mutations and possibly other homologous recombination deficiency states.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 9-13 |
| Number of pages | 5 |
| Journal | Journal of Managed Care Medicine |
| Volume | 22 |
| Issue number | 3 |
| State | Published - 2019 |
ASJC Scopus subject areas
- Health Policy